Engineering combination nanomedicines to overcome cancer resistance
RSC Advances · 2026 · 16 (6) · 5128-5167
DOI: 10.1039/d5ra08728g ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift RSC Advances, 2026. Verfasst von Hina Singh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biomedical Sciences, School of Medicine, University of California Riverside CA 92521 USA Hina.Singh@medsch.ucr.edu. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 258 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Lundbeck Foundation, Indian Council of Medical Research, Novo Nordisk Fonden.
Abstract (Originalsprache)
This review examines engineered combination nanomedicine strategies that integrate co-delivery platforms, tumor microenvironment targeting, and predictive translational models to overcome cancer drug resistance.
Autor:innen und Institutionen
- Division of Biomedical Sciences, School of Medicine, University of California Riverside CA 92521 USA Hina.Singh@medsch.ucr.edu.
- Department of Food Science and Biotechnology, Sejong University Gwangjin Gu Seoul 05006 Republic of Korea.
- Faculty of Biotechnology, University of Surabaya Raya Kalirungkut, Kalirungkut Surabaya 60293 Indonesia.
- Center of Excellence for Food Products and Health Supplements for Degenerative Conditions, University of Surabaya Surabaya 60293 Indonesia.
- Faculty of Life, Health and Allied Sciences, Institute of Technology and Management, ITM Vocational University Vadodara 391760 India.
- Applied Nano-Bio Therapeutics Laboratory, Department of Periodontics, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences Chennai 600 077 India.
ORCID-Profile: Aruchamy Mohanprasanth, Muthupandian Saravanan, Priyanka Singh
Förderung
- Lundbeck Foundation
- Indian Council of Medical Research
- Novo Nordisk Fonden
- Danmarks Frie Forskningsfond
Zitieren
APA
Singh, H., Balusamy, S. R., Sukweenadhi, J., Shrivastav, A., Mohanprasanth, A., Saravanan, M., Mijakovic, I., & Singh, P. (2026). Engineering combination nanomedicines to overcome cancer resistance. RSC Advances, 16(6), 5128-5167. https://doi.org/10.1039/d5ra08728g
Vancouver
Singh H, Balusamy SR, Sukweenadhi J, Shrivastav A, Mohanprasanth A, Saravanan M, et al. Engineering combination nanomedicines to overcome cancer resistance. RSC Advances. 2026;16(6):5128-5167. doi:10.1039/d5ra08728g
BibTeX
@article{Singh2026,
author = {Singh, Hina and Balusamy, Sri Renukadevi and Sukweenadhi, Johan and Shrivastav, Anupama and Mohanprasanth, Aruchamy and Saravanan, Muthupandian and Mijakovic, Ivan and Singh, Priyanka},
title = {Engineering combination nanomedicines to overcome cancer resistance},
journal = {RSC Advances},
year = {2026},
volume = {16},
number = {6},
pages = {5128--5167},
doi = {10.1039/d5ra08728g}
}
EUVIMED